HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Travere Therapeutics (NASDAQ: TVTX) and maintained a price target of $67 for the stock. This reaffirms the firm's positive outlook on the company's performance.